What Is Tirzepatide?
Tirzepatide is one of the novel anti-diabetic drugs that recently received FDA approval (2022) after being patented by Eli Lilly and Co in 2016. Since then, the drug has become an important instrument in the management of patients with type 2 diabetes.
Tirzepatide is a 39 amino acid molecule that offers dual activity over two important endogenous peptides–these are Glucose-Dependent Insulinotropic Polypeptide (GIP) and Glucagon-Like Peptide-1 (GLP-1). GIP and GLP-1 are naturally secreted into the gut when the food is taken in. Once released, GIP causes pancreatic beta-cells to increase their insulin production, while at the same time it inhibits gastric emptying. Moreover, GIP is able to decrease the breakdown of lipids. GLP-1 also works similarly but through a slightly different mechanism. This ultimately slows down the sudden rise of glucose in the body after a meal. The slowed gastric emptying promotes satiety, thus improving weight loss. The dual action of tirzepatide mimicking both GIP and GLP-1 makes this molecule different and stronger than other GLP-1 analogs. This is supported by recent research by Juan P Frías and colleagues in which they proved that tirzepatide is superior to semaglutide, another potent GLP-1 analog.